参考文献/References:
[1] Zhang JY,Chen QQ,Li J,et al. Neuraminidase 1 and its inhibitors from Chinese herbal medicines:an emerging role for cardiovascular diseases[J]. Am J Chin Med,2021,49(4):843-862.
[2] Bonten EJ,Annunziata I,d’Azzo A. Lysosomal multienzyme complex:pros and cons of working together[J]. Cell Mol Life Sci,2014,71(11):2017-2032.
[3] Varki A. Sialic acids in human health and disease[J]. Trends Mol Med,2008,14(8):351-360.
[4] Vaduganathan M,Mensah GA,Turco JV,et al. The global burden of cardiovascular?diseases and risk[J]. J Am Coll Cardiol,2022,80(25):2361-2371.
[5] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志,2022,37(6):553-578.
[6] Casscells SW,Granger E,Kress AM,et al. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases[J]. Circ Cardiovasc Qual Outcomes,2009,2(2):108-115.
[7] Pushpakom S,Iorio F,Eyers PA,et al. Drug repurposing:progress,challenges and recommendations[J]. Nat Rev Drug Discov,2019,18(1):41-58.
[8] Wang DW,Li S,Jiang JG,et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis[J]. Sci China Life Sci,2019,62(2):187-202.
[9] Demina EP,Smutova V,Pan X,et al. Neuraminidases 1 and 3 trigger atherosclerosis by desialylating low‐density lipoproteins and increasing their uptake by macrophages[J]. J Am Heart Assoc,2021,10(4):e18756.
[10] Betteridge KB,A rkill KP,N eal CR,et al. Sialic acids regulate microvessel permeability,revealed by novel in vivo studies of endothelial glycocalyx structure and function[J]. J Physiol,2017,595(15):5015-5035.
[11] Yang A,G yulay G,M itchell M,et al. Hypomorphic sialidase expression decreases serum cholesterol by downregulation of VLDL production in mice[J]. J Lipid Res,2012,53(12):2573-2585.
[12] White EJ,Gyulay G,Lhoták ?,et al. Sialidase down-regulation reduces non-HDL cholesterol,inhibits leukocyte transmigration,and attenuates atherosclerosis in ApoE knockout mice[J]. J Biol Chem,2018,293(38):14689-14706.
[13] Sieve I,Ricke-Hoch M,Kasten M,et al. A positive feedback loop between IL-1β,LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages[J]. Vascul Pharmacol,2018,103-105:16-28.
[14] Ivanova EA,Myasoedova VA,Melnichenko AA,et al. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases[J]. Oxid Med Cell Longev,2017,2017:1273042.
[15] Feng CG,Zhang L,Almulki L,et al. Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1[J]. J Leukoc Biol,2011,90(2):313-321.
[16] Gayral S,Garnotel R,Castaing-Berthou A,et al. Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3Kγ pathway[J]. Cardiovasc Res,2014,102(1):118-127.
[17] Kawecki C,Bocquet O,Schmelzer CEH,et al. Identification of CD36 as a new interaction partner of membrane NEU1:potential implication in the pro-atherogenic effects of the elastin receptor complex[J]. Cell Mol Life Sci,2019,76(4):791-807.
[18] Bocquet O,Tembely D,Rioult D,et al. Characterization of novel interactions with membrane NEU1 highlights new regulatory functions for the elastin receptor complex in monocyte interaction with endothelial cells[J]. Cell Biosci,2021,11(1):206.
[19] Frangogiannis NG. Regulation of the inflammatory response in cardiac repair[J]. Circ Res,2012,110(1):159-173.
[20] Hausenloy DJ,Yellon DM. Myocardial ischemia-reperfusion injury:a neglected therapeutic target[J]. J Clin Invest,2013,123(1):92-100.
[21] Allendorf DH,Franssen EH,Brown GC. Lipopolysaccharide activates microglia via neuraminidase 1 desialylation of toll‐like receptor 4[J]. J Neurochem,2020,155(4):403-416.
[22] Heimerl M,Sieve I,Ricke-Hoch M,et al. Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages[J]. Basic Res Cardiol,2020,115(6):62.
[23] Zhang L,Wei TT,Li Y,et al. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases[J]. Circulation,2018,137(13):1374-1390.
[24] Ong SB,Gustafsson AB. New roles for mitochondria in cell death in the reperfused myocardium[J]. Cardiovasc Res,2012,94(2):190-196.
[25] Süer G?kmen S,Kazezo?lu C,Sunar B,et al. Relationship between serum sialic acids,sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction[J]. Clin Chem Lab Med,2006,44(2):199-206.
[26] Yuan Y,Cruzat VF,Newsholme P,et al. Regulation of SIRT1 in aging:roles in mitochondrial function and biogenesis[J]. Mech Ageing Dev,2016,155:10-21.
[27] Guo Z,Fan D,Liu FY,et al. NEU1 regulates mitochondrial energy metabolism and oxidative stress post-myocardial infarction in mice via the SIRT1/PGC-1 Alpha axis[J]. Front Cardiovasc Med,2022,9:821317.
[28] 王晓英,刘盼,韩丹. 急性冠脉综合征患者血浆Neu5Ac、sLRP-1表达变化及临床意义[J]. 国际检验医学杂志,2022,43(8):934-939.
[29] Schiattarella GG,Hill JA. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload[J]. Circulation,2015,131(16):1435-1447.
[30] Nakamura M,Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol,2018,15(7):387-407.
[31] Chen QQ,Ma GX,Liu JF,et al. Neuraminidase 1 is a driver of experimental cardiac hypertrophy[J]. Eur Heart J,2021,42(36):3770-3782.
[32] Deng W,Ednie AR,Qi J,et al. Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure[J]. Basic Res Cardiol,2016,111(5):57.
[33] Verdonschot JAJ,Wang P,van Bilsen M,et al. Metabolic profiling associates with disease severity in nonischemic dilated cardiomyopathy[J]. J Card Fail,2020,26(3):212-222.
[34] Li CZ,Zhao MM,Xiao L,et al. Prognostic value of elevated levels of plasma N-acetylneuraminic acid in patients with heart failure[J]. Circ Heart Fail,2021,14(11):e008459.
[35] Cardinale D,Colombo A,Bacchiani G,et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation,2015,131(22):1981-1988.
[36] Swain SM,Whaley FS,Ewer MS. Congestive heart failure in patients treated with doxorubicin[J]. Cancer,2003,97(11):2869-2879.
[37] Zamorano JL,L ancellotti P,R odriguez Mu?oz D,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines[J]. Eur Heart J ,2016,37(36):2768-2801.
[38] Osataphan N,Phrommintikul A,Chattipakorn SC,et al. Effects of doxorubicin‐induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function:Insights for future interventions[J]. J Cell Mol Med,2020,24(12):6534-6557.
[39] Qin Y,Lv C,Zhang X,et al. Neuraminidase1 inhibitor protects against doxorubicin-induced cardiotoxicity via suppressing Drp1-dependent mitophagy[J]. Front Cell Dev Biol,2021,9:802502.
[40] Lee MMY,McMurray JJY,Lorenzo-Almorós A,et al. Diabetic cardiomyopathy[J]. Heart,2019,105(4):337-345.
[41] Jia G,DeMarco VG,Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol,2016,12(3):144-153.
[42] Wang M,Zhang WB,Zhou BQ,et al. The signal transduction pathway of PKC/NF-κB/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats[J]. Cardiovasc Diabetol,2009,8:8.
[43] Guo Z,Tuo H,Tang N,et al. Neuraminidase 1 deficiency attenuates cardiac dysfunction,oxidative stress,fibrosis,inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice[J]. Int J Biol Sci,2022,18(2):826-840.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(11):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(11):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(11):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(11):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(11):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(11):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(11):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]